GSK3 inhibitors: Development and therapeutic potential

TY - JOUR

T1 - GSK3 inhibitors

T2 - Development and therapeutic potential

AU - Cohen, Philip

AU - Goedert, Michel

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Glycogen synthase kinase-3 (GSK3) was initially identified more than two decades ago as an enzyme involved in the control of glycogen metabolism. In recent years it has been shown to have key roles in regulating a diverse range of cellular functions, which have prompted efforts to develop GSK3 inhibitors as therapeutics. Here, we describe the biology of GSK3 relevant to its potential as a target for diabetes and neurodegenerative diseases, and discuss progress in the development of GSK3 inhibitors.

AB - Glycogen synthase kinase-3 (GSK3) was initially identified more than two decades ago as an enzyme involved in the control of glycogen metabolism. In recent years it has been shown to have key roles in regulating a diverse range of cellular functions, which have prompted efforts to develop GSK3 inhibitors as therapeutics. Here, we describe the biology of GSK3 relevant to its potential as a target for diabetes and neurodegenerative diseases, and discuss progress in the development of GSK3 inhibitors.

UR - https://www.scopus.com/pages/publications/3042635178

U2 - 10.1038/nrd1415

DO - 10.1038/nrd1415

M3 - Review article

C2 - 15173837

AN - SCOPUS:3042635178

SN - 1474-1776

VL - 3

SP - 479

EP - 487

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

IS - 6

ER -